The efficacy of iclaprim against Staphylococcus aureus ATCC 25923 and its corresponding isogenic TK-deficient mutant S. aureus strain AH 1246 mixed with cytodex beads was studied in a mouse abscess infection model. Iclaprim (2-80 mg kg À1
INTRODUCTION
Iclaprim, a bacterial dihydrofolate reductase (DHFR) inhibitor (DHFRi), has potent in vitro activity against Gram-positive antibiotic-sensitive and -resistant bacteria [1] . However, as with other DHFRis, both in vitro and in vivo activity is impacted on by the presence of free thymidine, which can bypass the requirement for DHFR in the nucleotide biosynthetic pathway, thereby decreasing the susceptibility of bacteria to DHFRis. The commercially available media for in vitro testing contain thymidine [2] , and mouse plasma contains approximately 300-fold higher levels of thymidine than human plasma [3] [4] [5] . However, the conventional mouse abscess model is used to evaluate the efficacy of iclaprim because of its convenience, low cost and practicality compared to the use of non-human primates. To offset the impact of these high levels of free thymidine in mice, a thymidine kinase (TK)-deficient strain of Staphylococcus aureus was used to characterize the efficacy of iclaprim and define the PK/PD parameters related to its efficacy in a mouse abscess model.
METHODS

Antimicrobial agents
Iclaprim powder (Motif BioSciences, Princeton, NJ, USA) was used in the in vivo studies after resuspension in sterile deionized water.
Bacterial growth media
Trypicase soy agar (TSA) plates (BBL, Franklin Lakes, NJ, USA), brain heart infusion (BHI) broth (BBL, Franklin Lakes, NJ, USA) and Cytodex beads (Sigma-Aldrich, St Louis, MO, USA) were used. The standard Clinical and Laboratory Standards Institute (CLSI) microdilution technique [6] was used to determine the minimum inhibitory concentration (MIC) (performed done in triplicate) for the strains employed in these studies.
Bacterial strains and bacteria culture A wild-type S. aureus strain (S. aureus ATCC 25923) and its respective TK-deficient S. aureus strain (S. aureus AH 1246) were supplied by Motif BioSciences (Princeton, NJ, USA). The TK mutant was derived as described by Haldimann et al. [7] . Virulence studies determined that the fitness of the TK knockout was not affected. S. aureus was grown on TSA plates at 37 C in 5 % CO 2 . The bacterial inoculum was prepared by resuspending several colonies of an overnight streak culture in saline and adjusting a 1 : 10 dilution of the suspension to an optical density (OD) of 0.1 at 625 nm. The adjusted suspension was diluted 1 : 2 in prepared cytodex beads [1 gram/50 ml phosphate-buffered saline (PBS)] to a final concentration of 5.0Â10 5 c.f.u. ml
À1
. Bacterial counts were performed to determine the inoculum size. For consistency of infection, the wild-type and mutant were prepared at the same inoculum concentration.
Animals CD-1 female mice (weighing 18 to 22 grams) from Charles River Laboratories (Wilmington, MA, USA) were acclimated for 5 days prior to the first study day. All studies were performed under approved Institutional Animal Care and Use Committee (IACUC) protocols and conform to Office of Laboratory Animal Welfare(OLAW) standards as set forth by the National Research Council's Guide for the Care and Use of Laboratory Animals [8] . Animals had free access to food and water throughout the study and the food and water were enriched.
Infection studies
Mice (n=5 per group) were infected with a bacterial inoculum of 5Â10 5 c.f.u. per mouse via subcutaneous injection (0.2 ml of the bacterial/Cytodex injection volume) using an adapted murine infection model for both pharmacokinetic and pharmacodynamic studies [9] . Two hours post-infection, the mice were treated with iclaprim at concentrations ranging from 2 to 80 mg kg
À1
. At the time of treatment (2 h), one group of infected mice were euthanized, and abscesses were aseptically removed, homogenized, serially diluted and plated for bacterial enumeration. This group served as the time 0 untreated controls. Twenty-four hours after the initiation of treatment, the remaining animals, including a group of untreated mice, were euthanized and abscesses were processed for bacterial burden. The total dose (2, 10, 20, 40 and 80 mg kg À1 ) of iclaprim was fractionated. These dose-ranging doses were chosen based on other iclaprim animal infection models and to establish which dose works best in this model (unpublished data). Mice were treated with either a q12h, q8h or q6h dose schedule so that the fractionated drug dosing equalled the q24h (single dose) schedule. Abscesses were processed for bacterial load as described above. ) were calculated for all three PK/PD parameters versus the change in log 10 c.f.u. g À1 of abscess from the start of treatment (T=0 non-treated controls). Pharmacokinetic analysis was accomplished through non-compartmental analysis using WinNonLin (Pharsight Corporation, Mountain View, CA, USA).
Pharmacokinetic studies
Statistical analysis
The mean values and standard deviations were calculated for each dose group. Static dose was determined based on the mean values as well as the change in c.f.u.s from the initiation of treatment (T=0). GraphPad Prism (GraphPad Software, Inc) was employed to calculate the EC 50 and E max values for each dosing schedule, as well as determining the curve fit using a four-parameter variable-slope non-linear regression analysis (Hill equation).
RESULTS
The wild-type S. aureus and its corresponding TK mutant experienced similar growth. The MIC for iclaprim against the S. aureus ATCC 25923 and the corresponding TK mutant used in these studies was 0.12 µg ml , respectively. In contrast, poor antibacterial activity was observed against the corresponding wild-type (TK-competent) S. aureus strain, ATCC 25923, at all doses tested.
C max , the mean residence time (MRT) and the AUC for each dose against S. aureus AH1246 are listed in Table 1 . Iclaprim exhibited some nonlinear pharmacokinetics at the lowest doses. All of the dose concentrations tested achieved plasma concentration levels above the MIC for S. aureus AH1246 (0.12 µg ml À1 ). Fig. 1 shows each PK/PD parameter versus the log 10 c.f.u. data normalized to the T=0 controls for each dosing regimen. Non-linear regression and the Hill equation were utilized to determine the maximum effect (E max ) and the dose required to obtain 50 % of the E max (EC 50 ). The q8h, q12h and q24h dosing schedules demonstrated similar static doses and EC 50 s. The q6h dosing did reveal a slight increase in the dose required to achieve a static dose and EC 50 at 28 and 35.1 mg kg
À1
, respectively ( Table 2 ). The maximum reduction of the bacterial load in the abscess when compared to that in the 24 h untreated animals ranged from 1.99 to 2.62 log 10 c.f.u. g À1 of abscess over the four dosing schedules (Table 2) .
Correlating the PK data with the bioburden abscess data, R 2 values of 0.91, 0.87 and 0.70 were determined for AUC/ MIC, C max /MIC and %T>MIC, respectively (Fig. 1a-c) . For stasis, the AUC/MIC ratio was 5 and the %T>MIC was 2.8. For a 1 log 10 reduction, the AUC/MIC ratio was 12.5 and the %T>MIC was approximately 5.
DISCUSSION
This in vivo rodent model demonstrated the in vivo efficacy of a DHFRi, iclaprim, in a mouse abscess model and delineated its preliminary PK/PD relationships to efficacy. For both antimicrobial and oncological DHFRis, the standard murine model has been difficult to utilize to determine the PK/PD relationship for clinically relevant doses because the mouse has up to 300-fold higher levels of free thymidine compared to humans. In this preliminary study, fractionation of the iclaprim dose was conducted against the TK-deficient S. aureus strain AH 1246 [10] . Dosing at q8h and q12h intervals resulted in similar static doses with respect to the q24h dosing, with a static dose of approximately 14 mg kg
À1
. Only q6h dosing resulted in a slightly higher static dose. In the current study, the AUC/MIC (R 2 of 0.91) correlated best with efficacy. A prior neutropenic, murine thigh infection model was used to define the PK/ PD index linked to the efficacy of iclaprim against S. aureus 29 213 and Streptococcus pneumoniae ATCC 10813 [11] . The AUC/MIC was the PD parameter that was closely linked to efficacy against both these organisms. However, because wild-type bacteria were used, it was not possible to identify the PK/PD magnitude in that model with those strains. Therefore, this study demonstrated the usefulness of a TK-deficient mutant, compared to wildtype strains, for evaluating the efficacy of DHFRis in rodent models of infection. Further studies that include both sensitive and resistant clinical isolates are needed to confirm these findings.
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